MAPK3 and ovarian carcinoma: To further verify that AGO1 modulated the ovarian cancer cell functions via ERK1/2 not P38, we used the ERK1/2 inhibitor (LY3214996) and P38 inhibitor (SB203580) to inactivate the phosphorylation of ERK1/2 and P38, respectively.